---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102433"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:44:31.910599+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cogent reports positive SUMMIT trial, Q2 net loss $73.5M; pro-forma cash $453M

## Summary
- SUMMIT trial met primary endpoint: TSS improvement 8.91 points vs placebo (p=0.0002); 87.4% bezuclastinib patients had ≥50% tryptase reduction.
- Upcoming milestones: PEAK and APEX top-line results in 2H 2025; NDA submission by end of 2025.
- Q2 net loss $73.5M (vs $59.0M YoY); R&D $62.2M; G&A $13.4M; cash $237.8M at June 30, 2025.
- Pro-forma cash $453M including $215.8M net from July upsized offering; $400M debt facility with SLR Capital.
- Inducement grants to 6 new employees: 172,450 options at $9.00, 10-yr term, 4-yr vest.

## SEC filing metadata
- accession: 0000950170-25-102433
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/0000950170-25-102433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102433
- JSON: https://secwatch.observer/filing/0000950170-25-102433.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.